These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 30858122

  • 1. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways.
    Essam RM, Ahmed LA, Abdelsalam RM, El-Khatib AS.
    Life Sci; 2019 Apr 01; 222():245-254. PubMed ID: 30858122
    [Abstract] [Full Text] [Related]

  • 2. Phosphodiesterase-4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP/CREB signaling system.
    Jabaris SS, Sumathy H, Girish R, Narayanan S, Sugumar M, Saravana Babu C, Thanikachalam S, Thanikachalam M.
    Brain Res; 2015 Oct 05; 1622():279-91. PubMed ID: 26168894
    [Abstract] [Full Text] [Related]

  • 3. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice.
    Wang B, Zhu X, Yu S, Xue H, Deng L, Zhang Y, Zhang Y, Liu Y.
    Biochem Biophys Res Commun; 2024 Aug 30; 722():150170. PubMed ID: 38797152
    [Abstract] [Full Text] [Related]

  • 4. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.
    Izikki M, Raffestin B, Klar J, Hatzelmann A, Marx D, Tenor H, Zadigue P, Adnot S, Eddahibi S.
    J Pharmacol Exp Ther; 2009 Jul 30; 330(1):54-62. PubMed ID: 19386793
    [Abstract] [Full Text] [Related]

  • 5. Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway.
    Saroj P, Bansal Y, Singh R, Akhtar A, Sodhi RK, Bishnoi M, Sah SP, Kuhad A.
    Inflammopharmacology; 2021 Apr 30; 29(2):499-511. PubMed ID: 33517508
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
    Ikari J, Michalski JM, Iwasawa S, Gunji Y, Nogel S, Park JH, Nelson AJ, Farid M, Wang X, Schulte N, Basma H, Toews ML, Feghali-Bostwick C, Tenor H, Liu X, Rennard SI.
    Am J Respir Cell Mol Biol; 2013 Oct 30; 49(4):571-81. PubMed ID: 23656623
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling.
    Wójcik-Pszczoła K, Chłoń-Rzepa G, Jankowska A, Ślusarczyk M, Ferdek PE, Kusiak AA, Świerczek A, Pociecha K, Koczurkiewicz-Adamczyk P, Wyska E, Pękala E, Gosens R.
    Int J Mol Sci; 2020 Jun 03; 21(11):. PubMed ID: 32503342
    [Abstract] [Full Text] [Related]

  • 10. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.
    Ding H, Li N, He X, Liu B, Dong L, Liu Y.
    Int Urol Nephrol; 2017 Oct 03; 49(10):1723-1730. PubMed ID: 28756610
    [Abstract] [Full Text] [Related]

  • 11. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.
    Kwak HJ, Park KM, Choi HE, Chung KS, Lim HJ, Park HY.
    Cell Signal; 2008 May 03; 20(5):803-14. PubMed ID: 18276108
    [Abstract] [Full Text] [Related]

  • 12. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.
    Tao X, He H, Peng J, Xu R, Fu J, Hu Y, Li L, Yang X, Feng X, Zhang C, Zhang L, Yu X, Shen A, Huang K, Fu Q.
    Pharmacol Res; 2022 Jan 03; 175():106004. PubMed ID: 34826603
    [Abstract] [Full Text] [Related]

  • 13. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.
    Togo S, Liu X, Wang X, Sugiura H, Kamio K, Kawasaki S, Kobayashi T, Ertl RF, Ahn Y, Holz O, Magnussen H, Fredriksson K, Skold CM, Rennard SI.
    Am J Physiol Lung Cell Mol Physiol; 2009 Jun 03; 296(6):L959-69. PubMed ID: 19304913
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.
    Cortijo J, Iranzo A, Milara X, Mata M, Cerdá-Nicolás M, Ruiz-Saurí A, Tenor H, Hatzelmann A, Morcillo EJ.
    Br J Pharmacol; 2009 Feb 03; 156(3):534-44. PubMed ID: 19154443
    [Abstract] [Full Text] [Related]

  • 16. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
    Lehrke M, Kahles F, Makowska A, Tilstam PV, Diebold S, Marx J, Stöhr R, Hess K, Endorf EB, Bruemmer D, Marx N, Findeisen HM.
    J Mol Cell Cardiol; 2015 Apr 03; 81():23-33. PubMed ID: 25640159
    [Abstract] [Full Text] [Related]

  • 17. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
    Cazzola M, Calzetta L, Rogliani P, Matera MG.
    Expert Opin Drug Discov; 2016 Jul 03; 11(7):733-44. PubMed ID: 27169612
    [Abstract] [Full Text] [Related]

  • 18. Roflumilast, a Phosphodiesterases-4 (PDE4) Inhibitor, Alleviates Sepsis‑induced Acute Kidney Injury.
    Xu X, Liao L, Hu B, Jiang H, Tan M.
    Med Sci Monit; 2020 May 25; 26():e921319. PubMed ID: 32449901
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.